occur. Grade 3 to 4 thrombocytopenia was not observed. All patients attained complete remission (CR). In the two cases where the leukemic clone was detectable by the primers employed in the PCR, molecular remission (MR) was also reached. Without further additional treatment, all patients had remained in CR/MR after a median follow-up of 36 (12-40) months.
These observations represent an advance in the treatment of T-LGL leukemia. The advantages of FND are a brief period of treatment (6 months), mild and acceptable toxicities, a high response rate and the important potential of inducing durable remission without maintenance medication.
We combined fludarabine with mitoxantrone and dexamethasone to maximize therapeutic efficacy, because in other lymphoproliferative diseases, fludarabine is less active as a single agent than in combinations with other drugs. Also, fludarabine had been reported to ameliorate the cytopenias associated with T-LGL leukemia, without eradicating the leukemic clone. 4 Furthermore, fludarabine alone or combined with cyclophosphamide was reported to induce only partial remissions in T-LGL leukemia. 5 Patient 1 in our study achieved a durable remission without mitoxantrone, a response indistinguishable from cases 2 and 3 achieving CR with FND. Hence, fludarabine and dexamethasone appear to be key components. Chromosomal abnormalities are a hallmark of both pediatric and adult acute lymphoblastic leukemia (ALL) (reviewed in Armstrong and Look 1 ) and there is substantial evidence that defects in the repair of DNA damage can play an important role in the development of lymphoid malignancies. Two major pathways for the repair of DNA double-strand breaks (DSB), considered as the most lethal form of DNA damage for eukaryotic cells, are known. 2 While during late S-and G 2 -phase DSB can be repaired by homologous recombination with the sister chromatid, non-homologous end joining (NHEJ) is the predominant if not exclusive pathway during G 0 -, G 1 -and early S-phase. NHEJ, however, is typically imprecise due to the end processing of DNA ends before ligation. One of the central components of NHEJ is the DNA ligase IV (LIGIV) (reviewed in Lieber et al.
3 ). It has been shown that mutations in the LIGIV gene could lead to the rare LIGIV syndrome, which clinically resembles the Nijmegen breakage syndrome (NBS). Since only few patients with LIGIV deficiency have been described, it is still unknown whether this syndrome, like NBS and ataxia teleangiectatica, is also associated with an increased cancer risk. However, the first patient with a known defect in NHEJ who was homozygous for a missense mutation in LIGIV developed an ALL at the age of 14 years (reviewed in O'Driscoll et al. 4 and Girard et al. 5 ). From the evidence presented above, LIGIV involved in NHEJ is a plausible candidate gene for a cancer predisposition syndrome. Thus, we aimed to test whether mutations in the gene encoding LIGIV might increase the risk of developing ALL during childhood. In this study, DNA from leukemic cells of 107 children under the age of 18 with newly diagnosed ALL (92 B-cell precursor ALL; 15 T-ALL) were analyzed for genetic variants in the LIGIV gene by DHPLC or sequencing. The proportion of leukemic blasts was above 70% in 102 probes, more than 50% in three and at least 37% in the remaining two samples prior Ficoll separation. In the primary screening for LIGIV mutations, the entire LIGIV gene of 57 ALL cell samples was analyzed by DHPLC or sequencing. Except for a single nucleotide polymorphism (SNP) at position 1977 of the LIGIV gene, which does not lead to an exchange of an amino acid (D568D), only two SNP were found in the N-terminal region (C-T, A3V and C-T, T9I). All alterations have been described previously. 6, 7 Consequently, 50 further samples were sequenced for these two N-terminal polymorphisms A3V and T9I alone. Additional 104 DNA samples of a healthy control population were sequenced for these two SNP alone.
In the control population, the allele frequencies of LIGIV A3V and T9I were 0.067 and 0.188, respectively. These results are consistent with the frequencies described previously in a larger British study. 6 Strikingly, the frequencies among children with ALL were not higher as it was expected but significantly lower. Within the ALL group, the A3V and T9I allele frequencies were 0.047 and 0.117, respectively. Overall, among the ALL patients only 20.6% carried at least one of the polymorphisms, while this rate was 34.6% within the control population. This difference is statistically significant (w 2 ¼ 5.2266, Po0.025). The results are summarized in Table 1 . No significant differences were observed concerning ALL immunophenotype, sex, age at diagnosis, survival rate, or risk of relapse.
These results implicate that the two polymorphisms A3V and T9I do not increase the risk of ALL in children, but rather suggest that they could convey a protective effect. Roddam et al. 6 reported a lower frequency of A3V and T9I in patients with multiple myeloma as compared to the control population and discussed their potential protective effects. However, in this study, no significant difference was found between ALL patients (n ¼ 70) and controls (n ¼ 220) regarding the frequencies of wild-type and variant LIGIV gene. Since multiple myeloma is not found in childhood and no age was provided for the ALL patients, it is reasonable to assume that this study population consisted of adults. In support of our study on childhood ALL, recent data indicate that T9I might reduce the risk for nonHodgkin's lymphomas as well. 8 The LIGIV isoform carrying the variants A3V and T9I has been shown to display a 2-to 3-fold reduced ligation activity. 5 Considering the essential role of DNA repair for the maintenance of genomic stability and the important functions of NHEJ for the repair of DSB, a protective effect of polymorphisms potentially decreasing the NHEJ activity in a central component of the NHEJ pathway might be surprising. However, there is growing evidence that NHEJ could be error-prone and could in fact create chromosomal translocations frequently seen in leukemic cells. Chromosomal translocations involving the MLL gene are found in about 80% of infant leukemias, and NHEJ could be involved in these recombination events as well. Some features point to a potential involvement of NHEJ in the creation of the chromosomal translocation t(12;21), the most common genetic rearrangement in childhood ALL, 1 resulting in the fusion protein ETV6/RUNX1 (TEL/AML1) (reviewed in Rassool 2 ). Thus, it seems possible that a decrease of NHEJ activity could reduce the formation of potentially threatening frameshift mutations and translocations and, thereby, prevent the development of cancer. Whether or not the polymorphisms A3V and T9I alone and in heterozygous form could influence the LIGIV activity, still remains to be elucidated. Letters to the Editor
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